Federal Register / Vol. 89, No. 24 / Monday, February 5, 2024 / Notices 7711 

** Request is for an October 1, 2024, 

implementation date, and the requestor 

intends to submit an NTAP application 

for FY 2026 consideration. 

These topics will not be presented 

during the March 19–20, 2024, meeting. 

CMS will solicit public comments 

regarding any clinical questions or 

coding options included for these 

procedure code topics in advance of the 

meeting continuing through the end of 

the respective public comment periods. 

Members of the public should send any 

questions or comments to the CMS 

mailbox at: ICDProcedureCodeRequest@

cms.hhs.gov. 

CMS intends to post a question-andanswer document in advance of the 

meeting to address any clinical or 

coding questions that members of the 

public may have submitted. Following 

the conclusion of the meeting, CMS will 

post an updated question-and-answer 

document to address any additional 

clinical or coding questions that 

members of the public may have 

submitted during the meeting that CMS 

was not able to address or that were 

submitted after the meeting. 

The NTAP-related ICD–10–PCS 

procedure code requests that do not 

involve the administration of a 

therapeutic agent and all non-NTAPrelated procedure code requests will 

continue to be presented during the 

virtual meeting on March 19, 2024, 

consistent with the standard meeting 

process. 

CMS will make all meeting materials 

and related documents available at: 

https://www.cms.gov/medicare/codingbilling/icd-10-codes/icd-10- 

coordination-maintenance-committeematerials. Any inquiries related to the 

procedure code topics scheduled for the 

March 19, 2024, ICD–10 C&M 

Committee meeting day that are under 

consideration for October 1, 2024, 

implementation should be sent to the 

CMS mailbox at: 

ICDProcedureCodeRequest@

cms.hhs.gov. 

ICD–10–CM Topics: 

1. Abnormal Anti-cyclic Citrullinated 

Peptide Antibody and/or 

Rheumatoid Factor Without Current 

or Prior Clinical Diagnosis of 

Rheumatoid Arthritis 

2. APOL1-mediated Kidney Disease 

3. Baked Egg Tolerance 

4. Baked Milk Tolerance 

5. Coding of Firearms Injuries Default 

6. DLG4-related Synaptopathy 

7. Flank Anatomical Specificity 

8. Glutamate Receptor, Ionotropic, 

Gene-related Neurodevelopmental 

Disorders 

9. Gulf War Illness 

10. Hyperoxaluria 

11. Post-exertional Malaise 

12. SCN2A-related Disorders 

13. SLC6A1-related Disorders 

14. STXBP1-related Disorders 

15. Usher Syndrome 

16. Addenda 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–02178 Filed 2–2–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–24–1402] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Surveillance of 

HIV-related service barriers among 

Individuals with Early or Late HIV 

Diagnoses (SHIELD)’’ to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on October 

06, 2023, to obtain comments from the 

public and affected agencies. CDC 

received two comments to the previous 

notice. This notice serves to allow an 

additional 30 days for public and 

affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Surveillance of HIV-related service 

barriers among Individuals with Early or 

Late HIV Diagnoses (SHIELD) (OMB 

Control No. 0920–1402, Exp. 05/31/ 

2026)—Revision—National Center for 

HIV, Viral Hepatitis, STD, and TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

National HIV Surveillance System 

(NHSS) data indicate that 36,940 

adolescents and adults received an HIV 

diagnosis in the United States and 

dependent areas in 2019. During 2015– 

2019, the overall rate of annual 

diagnoses decreased only slightly, from 

12.4 to 11.1 per 100,000 persons. 

Although not every jurisdiction reports 

complete laboratory data needed to 

identify the stage of infection, data from 

the majority of jurisdictions show that 

many of these cases were classified as 

Stage 0 (6.9%) or Stage 3 (21.5%) 

infection (i.e., cases diagnosed in early 

infection or late infection, respectively). 

Early and late diagnoses represent 

recent failures in prevention and testing 

systems, and opportunities to 


lotter on DSK11XQN23PROD with NOTICES1
7712 Federal Register / Vol. 89, No. 24 / Monday, February 5, 2024 / Notices 

understand needed improvements in 

these systems. 

The NHSS would classify HIV 

infections as Stage 0 if the first positive 

HIV test were within six months of a 

negative HIV test. Persons who received 

a diagnosis at Stage 0 (i.e., early 

diagnosis) could access HIV testing 

shortly after infection yet could not 

benefit from biomedical and behavioral 

interventions to prevent HIV infection. 

The federal Ending the HIV Epidemic in 

the U.S. (EHE) initiative prioritizes the 

provision of HIV preexposure 

prophylaxis (PrEP), syringe services 

programs, treatment as prevention 

efforts, and other proven 

interventions—as part of the Prevent 

pillar of the EHE initiative—to prevent 

new HIV infections. 

HIV infections are classified as Stage 

3 (AIDS) by the presence of an AIDSdefining opportunistic infection or by 

the lowest CD4 lymphocyte test result. 

Persons with Stage 3 infection at the 

time of their initial HIV diagnosis (i.e., 

late diagnosis) did not benefit from 

timely receipt of testing or HIV 

prevention interventions. They were 

likely unaware of their infection for a 

substantial length of time. 

Nationally, an estimated 13.3% of 

persons with HIV are unaware of their 

infection, contributing to an estimated 

40% of all ongoing transmission. 

Increasing early diagnosis is a crucial 

pillar of efforts to end HIV in the United 

States. Given the continued occurrence 

of HIV infections in the United States, 

the barriers and gaps associated with 

low uptake of HIV testing and 

prevention services must be addressed 

to reduce new infections and facilitate 

timely diagnosis and treatment. 

Individual- and systems-level factors 

likely contribute to barriers and gaps in 

testing and prevention. Therefore, CDC 

is sponsoring this data collection to 

improve understanding of barriers and 

gaps associated with new infection and 

late diagnosis in the era of multiple 

testing modalities and prevention 

options such as PrEP. These enhanced 

surveillance activities will identify 

actionable missed opportunities for 

early diagnosis and prevention, thus 

informing allocation of resources, 

development and prioritization of 

interventions, and evidence-based local 

and national decisions to improve HIV 

testing and address prevention gaps. 

The changes proposed in this request 

add a new qualitative data collection 

activity that encompasses a new consent 

form and a new data collection tool (Indepth Interview Guide) to conduct 

qualitative interviews to meet prevailing 

information needs and enhance the 

value of SHIELD data and minor edits 

to the approved SHIELD survey while 

remaining within the scope of the 

currently approved project purpose. The 

annualized burden hours of the project 

increased by 158 hours with these 

additions, for a total of 3,074 annualized 

burden hours. There are no costs to 

respondents other than time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Potential Eligible Participant ................... Recruitment Script English ..................................... 2,000 1 15/60 

Potential Eligible Participant ................... Recruitment Script Spanish .................................... 500 1 15/60 

Eligible Participant .................................. Consent for quantitative survey—English .............. 2,000 1 5/60 

Eligible Participant .................................. Consent—Spanish .................................................. 500 1 5/60 

Eligible Participant .................................. Survey—English ..................................................... 2,000 1 50/60 

Eligible Participant .................................. Survey—Spanish .................................................... 500 1 50/60 

Eligible Participant .................................. Consent for qualitative interview—English ............. 50 1 5/60 

Eligible Participant .................................. Consent for qualitative interview—Spanish ............ 50 1 5/60 

Eligible Participant .................................. In-depth Interview—English .................................... 50 1 90/60 

Eligible Participant .................................. In-depth Interview—Spanish ................................... 50 1 90/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–02172 Filed 2–2–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–24–0199; Docket No. CDC–2024– 

0008] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Import Permit. 

The goal of the information collection is 

to support the Public Health Service 

(PHS) Act and prevent the introduction, 

transmission, or spread of 

communicable diseases from foreign 

countries into the States or possessions, 

or from one State or possession into any 

other State or possession. 

DATES: CDC must receive written 

comments on or before April 5, 2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0008 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 


lotter on DSK11XQN23PROD with NOTICES1